Clinical Trial Update: A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the combination of obinutuzumab (GDC-0199) and ibrutinib in relapsed/refractory mantle cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Nantes University Hospital | Conditions: Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED